First Use of Tapinarof Monotherapy for Seborrhoeic Dermatitis: A Case Report


  • Naiem T. Issa Issa Research and Consulting, LLC, Springfield, VA
  • Michael Kaiser Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine Dr. Phillip Frost, Miami, USA



Seborrheic Dermatitis, Tapinarof


Abstract is missing (Short communication)


Download data is not yet available.


Szepietowski JC, Reich A, Wesołowska-Szepietowska E, Baran E, Group NQoLiD. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357-363. DOI:

Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol 2022 Dec 17 [Online ahead of print]. DOI:

Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol 2015; 3: 10.13188/2373-1044.1000019. DOI:

Keam SJ. Tapinarof cream 1%: first approval. Drugs 2022; 82: 1221-1228. DOI:

Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman-Yassky E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol 2020; 29: 481-489. DOI:

Gary G. Optimizing treatment approaches in seborrheic dermatitis. J Clin Aesthet Dermatol 2013; 6: 44.

Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review. JAMA Dermatol 2015; 151: 221-222. DOI:

Nogueira S, Rodrigues MA, Vender R, Torres T. Tapinarof for the treatment of psoriasis. Dermatol Ther 2022; 35: e15931. DOI:

Uppal SK, Chat VS, Kearns DG, Wu JJ. Topical agents currently in phase II or phase III trials for atopic dermatitis. J Drugs Dermatol 2020; 19: 956-959. DOI:

Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol 2017; 137: 2110-2119. DOI:

Sutter CH, Azim S, Wang A, Bhuju J, Simpson AS, Uberoi A, et al. Ligand-activation of the aryl hydrocarbon receptor up-regulates epidermal UDP-glucose ceramide glucosyltransferase and glucosylceramides. J Invest Dermatol 2023 Mar 31 [online ahead of print]. DOI:

Sekhon S, Koo J. Indirubin: a novel topical agent in the treatment of psoriasis. Br J Dermatol 2018; 178: 21-21. DOI:

Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol 2013; 133: 2023-2030. DOI:

Park HB, Goddard TN, Oh J, Patel J, Wei Z, Perez CE, et al. Bacterial autoimmune drug metabolism transforms an immunomodulator into structurally and functionally divergent antibiotics. Angewandte Chemie 2020; 132: 7945-7954. DOI:



How to Cite

Issa, N. T., & Kaiser, M. (2023). First Use of Tapinarof Monotherapy for Seborrhoeic Dermatitis: A Case Report. Acta Dermato-Venereologica, 103, adv12343.